Related Experiment Videos
In vitro approach to 'uremic cardiomyopathy'
D Weisensee1, I Löw-Friedrich, M Riehle
1Cinematic Cell Research Group, Hospital of the Johann Wolfgang Goethe-University, Frankfurt am Main, FRG.
Nephron
|January 1, 1993
Summary
Uremic toxins in chronic kidney disease patients negatively impact heart cell function, causing reduced contractility and arrhythmias. This study introduces a new method to identify these cardiotoxins in patient blood.
Area of Science:
- Cardiology
- Nephrology
- Toxicology
Background:
- Cardiovascular complications significantly impact patient prognosis in chronic renal failure.
- The specific role of retained uremic compounds in myocardial damage remains debated.
Purpose of the Study:
- To investigate the cardiotoxic effects of substances found in uremic patients' blood.
- To evaluate the impact of uremic toxins on cardiac myocyte contractility and function.
Main Methods:
- Utilized cultured spontaneously beating mouse cardiac myocytes.
- Employed a computer-assisted digital image analysis system for contractility assessment.
- Perfused myocytes with sera from hemodialysis patients and specific toxin solutions (creatinine, urea).
Main Results:
- 'Uremic sera', creatinine, and urea demonstrated dose-dependent reductions in myocyte contractility (inotropy).
- These compounds also induced arrhythmias and asynchronous contractions in the cultured heart cells.
- Concentration-dependent effects were observed for all tested substances.
Conclusions:
- The study identifies uremic sera, creatinine, and urea as detrimental to cardiac myocyte function.
- Proposes the myocyte perfusion technique as a valuable in vitro tool for identifying cardiotoxins in uremic patient body fluids.
- Highlights the potential for specific toxins to contribute to myocardial lesions in chronic renal failure.